| Summary of Net Revenue, Cost of Sales, Depreciation and Amortization, Operating Profit, and Interest Expense and Assets by Segment |
The following table shows, by segment: net revenue, cost of sales, depreciation and amortization, operating profit, and interest expense for the three and nine months ended August 31, 2026 and 2025:
|
|
|
|
|
|
|
|
|
|
|
For the three months ended August 31, |
|
|
|
2026 |
|
|
2025 |
|
Net revenue: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
7,650,234 |
|
|
$ |
7,820,877 |
|
PrepaCyte CB |
|
|
38,922 |
|
|
|
436 |
|
Public cord blood banking |
|
|
135,000 |
|
|
|
4,119 |
|
Total net revenue |
|
$ |
7,824,156 |
|
|
$ |
7,825,432 |
|
Cost of sales: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
1,434,684 |
|
|
$ |
1,666,952 |
|
PrepaCyte CB |
|
|
18,848 |
|
|
|
2,295 |
|
Public cord blood banking |
|
|
159,681 |
|
|
|
132,172 |
|
Total cost of sales |
|
$ |
1,613,213 |
|
|
$ |
1,801,419 |
|
Operating profit: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
2,198,587 |
|
|
$ |
2,032,929 |
|
PrepaCyte CB |
|
|
19,825 |
|
|
|
(4,340 |
) |
Public cord blood banking |
|
|
(24,681 |
) |
|
|
(128,053 |
) |
Total operating profit |
|
$ |
2,193,731 |
|
|
$ |
1,900,536 |
|
Depreciation and amortization: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
184,230 |
|
|
$ |
183,212 |
|
PrepaCyte CB |
|
|
249 |
|
|
|
2,481 |
|
Public cord blood banking |
|
|
— |
|
|
|
— |
|
Total depreciation and amortization |
|
$ |
184,479 |
|
|
$ |
185,693 |
|
Interest expense: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
438,305 |
|
|
$ |
538,219 |
|
PrepaCyte CB |
|
|
— |
|
|
|
— |
|
Public cord blood banking |
|
|
— |
|
|
|
— |
|
Total interest expense |
|
$ |
438,305 |
|
|
$ |
538,219 |
|
|
|
|
|
|
|
|
|
|
For the nine months ended August 31, |
|
|
|
2026 |
|
|
2025 |
|
Net revenue: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
23,008,793 |
|
|
$ |
23,558,484 |
|
PrepaCyte CB |
|
|
91,698 |
|
|
|
35,785 |
|
Public cord blood banking |
|
|
182,895 |
|
|
|
128,886 |
|
Total net revenue |
|
$ |
23,283,386 |
|
|
$ |
23,723,155 |
|
Cost of sales: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
4,533,144 |
|
|
$ |
5,020,695 |
|
PrepaCyte CB |
|
|
36,818 |
|
|
|
13,537 |
|
Public cord blood banking |
|
|
376,402 |
|
|
|
608,314 |
|
Total cost of sales |
|
$ |
4,946,364 |
|
|
$ |
5,642,546 |
|
Operating profit: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
4,295,579 |
|
|
$ |
4,922,731 |
|
PrepaCyte CB |
|
|
54,134 |
|
|
|
5,878 |
|
Public cord blood banking |
|
|
(193,507 |
) |
|
|
(479,428 |
) |
Total operating profit |
|
$ |
4,156,206 |
|
|
$ |
4,449,181 |
|
Depreciation and amortization: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
551,949 |
|
|
$ |
551,278 |
|
PrepaCyte CB |
|
|
746 |
|
|
|
16,370 |
|
Public cord blood banking |
|
|
— |
|
|
|
— |
|
Total depreciation and amortization |
|
$ |
552,695 |
|
|
$ |
567,648 |
|
Interest expense: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
1,342,931 |
|
|
$ |
1,584,307 |
|
PrepaCyte CB |
|
|
— |
|
|
|
— |
|
Public cord blood banking |
|
|
— |
|
|
|
— |
|
Total interest expense |
|
$ |
1,342,931 |
|
|
$ |
1,584,307 |
|
The following table shows the assets by segment as of August 31, 2026 and November 30, 2025:
|
|
|
|
|
|
|
|
|
|
|
As of |
|
|
As of |
|
|
|
August 31, 2026 |
|
|
November 30, 2025 |
|
Assets: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell
service |
|
$ |
61,402,075 |
|
|
$ |
60,788,322 |
|
PrepaCyte CB |
|
|
87,714 |
|
|
|
135,379 |
|
Public cord blood banking |
|
|
812,910 |
|
|
|
804,813 |
|
Total assets |
|
$ |
62,302,699 |
|
|
$ |
61,728,514 |
|
|